ID

12971

Descrição

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT00270400

Link

https://clinicaltrials.gov/show/NCT00270400

Palavras-chave

Versões (1)
  1. 08/01/2016 08/01/2016 -
Titular dos direitos

CC BY-NC 3.0

Transferido a

8 de janeiro de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Heart Failure, Congestive NCT00270400

Inglês

Eligibility Heart Failure, Congestive NCT00270400

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
Descrição

congestive heart failure

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1275491
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Descrição

has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2]
C0012963
UMLS CUI [3]
C0012798
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
Descrição

oral antiarrhythmic medications

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0003195
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Descrição

cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1980011
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Descrição

has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0005823
UMLS CUI [2]
C0036980
UMLS CUI [3]
C0948268
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Descrição

has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1980011
UMLS CUI [2]
C0013030
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Descrição

has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013030
UMLS CUI [2]
C0012963
UMLS CUI [3]
C0128513
UMLS CUI [4]
C0028193
UMLS CUI [5]
C0017887
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Descrição

requires an intravenous antiarrhythmic medication during the 48 hours before starting the study

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0003195
Voltar ao início da página

Similar models

Eligibility Heart Failure, Congestive NCT00270400

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
congestive heart failure
Item
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
boolean
C1275491 (UMLS CUI [1])
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Item
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
boolean
C0018802 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0012798 (UMLS CUI [3])
oral antiarrhythmic medications
Item
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
boolean
C0003195 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Item
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
boolean
C1980011 (UMLS CUI [1])
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Item
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
boolean
C0005823 (UMLS CUI [1])
C0036980 (UMLS CUI [2])
C0948268 (UMLS CUI [3])
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Item
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
boolean
C1980011 (UMLS CUI [1])
C0013030 (UMLS CUI [2])
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Item
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
boolean
C0013030 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0128513 (UMLS CUI [3])
C0028193 (UMLS CUI [4])
C0017887 (UMLS CUI [5])
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Item
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
boolean
C0003195 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial